Multiple sclerosis is a chronic autoimmune disease of the central nervous system that results
in varying degrees of disability. Progressive multiple sclerosis, characterized by a steady …

Purpose of review Multiple sclerosis (MS) is an immune-mediated disorder that affects the
central nervous system (CNS), often first affecting people in early adulthood. Although most …

The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-
modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding …

Despite the success of disease-modifying treatments in relapsing multiple sclerosis, for
many individuals living with multiple sclerosis, progressive disability continues to accrue …

Despite the fact that majority of patients with multiple sclerosis (MS) have relapsing-remitting
disease, many transition to secondary progressive disease (SPMS) over time. This transition …

Accumulating neurological disability has a substantial impact on the lives of patients with
multiple sclerosis (MS). As well as the established Expanded Disability Status Scale (EDSS) …

The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective
and personalized treatment, but the choice and management of disease-modifying therapies …

Background and purpose Effectiveness of autologous haematopoietic stem cell
transplantation (AHSCT) in relapsing–remitting multiple sclerosis (MS) is well known, but in …

While humanity struggles to develop a vaccine against SARS-CoV-2, it is imperative that
effective and affordable therapeutic strategies be evolved. Since a majority of the SARS-CoV …

In the past decades, multiple sclerosis (MS) treatment has experienced vast changes
resulting from major advances in disease-modifying therapies (DMT). Looking at the overall …